Gliosarcoma Global Market Report 2025

The gliosarcoma market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period was driven by increasing healthcare expenditure, a rising number of clinical trials, a growing global aging population, a higher prevalence of comorbidities such as diabetes and hypertension, and expanded healthcare insurance coverage.

The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period is expected to be driven by the increasing incidence of gliosarcoma, rising awareness of brain cancers, growth in research funding for brain cancer, increasing demand for personalized treatments, and the expansion of healthcare infrastructure. Key trends include advancements in diagnostic techniques, the development of targeted therapies, the availability of advanced imaging technologies, innovations in surgical techniques, and technological advancements in drug delivery systems.

The rising incidence of brain tumors is expected to drive growth in the gliosarcoma market. A brain tumor is an abnormal growth of cells in the brain, which can be either benign or malignant and may cause symptoms such as headaches, seizures, and vision problems. The increasing number of brain tumor cases is attributed to improved diagnostic technologies, heightened awareness, and environmental and lifestyle factors that may contribute to greater exposure to risk factors. Gliosarcoma treatment plays a crucial role in managing this aggressive and rare cancer, aiming to alleviate symptoms, extend survival, and enhance the patient’s quality of life. For example, in October 2022, the National Library of Medicine, a US-based biomedical library operated by the United States federal government, reported that in 2023, the United States recorded 94,390 new cases of brain and central nervous system (CNS) tumors, up from 93,470 cases in 2022. Malignant cases increased from 26,670 to 26,940, while non-malignant cases rose from 66,800 to 67,440. The growing incidence of brain tumors is thus fueling demand for gliosarcoma treatment.

Leading companies in the gliosarcoma market are focusing on developing advanced wearable technology to enhance cancer treatment and monitoring. Wearable devices are electronic gadgets worn on the body that track and analyze health data, offering real-time insights and improving patient engagement. For instance, in November 2024, Novocure Ltd., a UK-based oncology company, received U.S. Food and Drug Administration (FDA) approval for the use of Head Flexible Electrode (HFE) transducer arrays alongside Optune Gio for treating adult patients with glioblastoma multiforme (GBM). Optune Gio is a portable, wearable device that uses non-invasive arrays to deliver tumor-treating fields (TTFields), which apply physical forces to electrically charged components of dividing cancer cells, disrupting their rapid growth. The newly introduced HFE arrays are 50% thinner and one-third lighter than the ceramic discs used in the existing Optune Gio arrays, as they are made from a flexible polymer material, enhancing patient comfort and usability.

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences in a $1.3 billion deal. This acquisition strengthens Merck’s oncology portfolio by advancing innovative therapies for glioblastoma and other cancers, further expanding its expertise in cancer treatment. Modifi Biosciences, based in the U.S., specializes in developing treatments for glioblastoma, reinforcing Merck’s commitment to addressing complex oncological challenges.

Major players in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., Komipharm International Co. Ltd., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.

North America was the largest region in the gliosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gliosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gliosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gliosarcoma is a rare and aggressive brain tumor composed of both glial and sarcomatous tissue, primarily occurring in the cerebral hemisphere. It is studied to understand tumor biology and develop treatment strategies for glioblastoma and other brain malignancies.

The primary diagnostic methods for gliosarcoma include imaging techniques, histopathological examination, and biomarker testing. Imaging techniques, such as MRI, CT, and PET scans, are non-invasive methods used to visualize internal structures and detect abnormalities. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with end users including hospitals, cancer research institutes, and specialty clinics.

The gliosarcoma market research report is one of a series of new reports that provides gliosarcoma market statistics, including gliosarcoma industry global market size, regional shares, competitors with a gliosarcoma market share, detailed gliosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the gliosarcoma industry. This gliosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gliosarcoma market consists of revenues earned by entities by providing services such as molecular diagnostics, clinical trials and research, palliative care services, rehabilitation, and recovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gliosarcoma market also includes sales of diagnostic kits, research reagents, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.